An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities.
Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.
Ankylosing spondylitis, rheumatoid arthritis: 15 mg/day as a single dose. Patients with increased risk of adverse effects: Initial: 7.5 mg/day.
Acute exacerbations of osteoarthritis: 7.5 mg/day. Max: 15 mg/day as a single dose.
Adverse drug reactions: dyspepsia, headache, nausea, diarrhoea, abdominal pain, dizziness, flatulence, influenza-like symptoms, musculoskeletal and connective tissue signs and symptoms.